Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2006 1
2008 1
2009 3
2010 5
2011 4
2012 8
2013 12
2014 12
2015 22
2016 8
2017 19
2018 8
2019 24
2020 20
2021 8
2022 7
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Lung Cancer in Lithuania.
Gedvilaitė V, Danila E, Cicėnas S, Smailytė G. Gedvilaitė V, et al. Among authors: smailyte g. J Thorac Oncol. 2020 Sep;15(9):1401-1405. doi: 10.1016/j.jtho.2020.02.029. J Thorac Oncol. 2020. PMID: 32854913 Free article. No abstract available.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study.
Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, Siesling S, van der Zwan JM, Van Eycken L, Visser O, Žakelj MP, Anderson LA, Bella F, Kaire I, Otter R, Stiller CA, Trama A; RARECAREnet working group. Gatta G, et al. Lancet Oncol. 2017 Aug;18(8):1022-1039. doi: 10.1016/S1470-2045(17)30445-X. Epub 2017 Jul 4. Lancet Oncol. 2017. PMID: 28687376 Free article.
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group. Allemani C, et al. Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26. Lancet. 2015. PMID: 25467588 Free PMC article.
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group. Ray-Coquard I, et al. Eur J Surg Oncol. 2019 Jan;45(1):67-74. doi: 10.1016/j.ejso.2017.09.025. Epub 2017 Nov 3. Eur J Surg Oncol. 2019. PMID: 29108961 Review.
153 results